The Acton, Massachusetts-based company first broke ground on the plant in June 2022. It strengthens the company’s global operational capabilities and supply chain resiliency with expanded Omnipod automated insulin delivery system manufacturing.
Insulet said the 400,000-square-foot facility comes in at twice the size of its highly automated manufacturing plant in Acton. Currently, the company has more than 350 full-time employees at the Malaysia facility. It plans to grow its headcount there to more than 1,000 in the coming years as part of a $200 million investment in the area.
The company designed the facility with sustainable elements in an effort to eventually achieve both Green Building Index (GBI) certification and Leadership in Energy and Environmental Design (LEED) Silver certification. These certifications come as part of Insulet’s plan to minimize environmental impact.
Across nearly 13 acres, the site includes more than 5,700 solar panels, generating about 15% of the building’s power needs. The company had an underground rainwater harvesting system built to reduce potential stress to local water sources, too. Comprised of three rainwater capture units, it has the capacity to satisfy 30% of the landscaping water needs. Insulet said the construction also included energy-efficient equipment and construction materials used as hardscape material. This reduced heat island effects.
“Insulet’s remarkable growth is driven by our market-leading Omnipod 5, the first and only tubeless automated insulin delivery system in the U.S.,” said Jim Hollingshead, Insulet president and CEO. “Our new state-of-the-art manufacturing facility in Malaysia positions us strategically to stay ahead of the huge demand for Omnipod, ensuring our customers have uninterrupted access to our products from this thriving region with great talent.”
